DexCom Inc (DXCM)

Currency in USD
79.28
-1.49(-1.84%)
Closed·
After Hours
79.99+0.71(+0.90%)
·
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
78.9380.86
52 wk Range
57.5293.25
Key Statistics
Prev. Close
80.77
Open
80.57
Day's Range
78.93-80.86
52 wk Range
57.52-93.25
Volume
5.24M
Average Volume (3m)
3.56M
1-Year Change
9.65%
Book Value / Share
6.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
102.08
Upside
+28.76%
Members' Sentiments
Bearish
Bullish
ProTips
11 analysts have revised their earnings upwards for the upcoming period

DexCom Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

DexCom Inc Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc SWOT Analysis


CGM Market Leade
Explore DexCom's dominant position in continuous glucose monitoring technology, driving innovation and expanding market reach in diabetes management
Financial Resilience
Delve into DexCom's robust financial performance, with $4.15 billion in trailing twelve-month revenue and a strong gross margin of 59.43%
Growth Catalysts
Uncover DexCom's strategic expansion into Type 2 diabetes market and international growth potential, positioning the company for sustained success
Analyst Outlook
Average price target of $99, with analysts projecting potential outperformance and anticipating DexCom to exceed its conservative 2025 revenue guidance
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q2/2025

  • DexCom Q2 2025 EPS of $0.48 beat $0.45 forecast; revenue of $1.16B exceeded $1.12B estimate, driving 0.44% stock rise in aftermarket trading
  • Revenue grew 15% YoY to $1.16B, with U.S. revenue up 15% to $841M and international revenue rising 16% to $316M
  • Full-year revenue guidance raised to $4.600-$4.625B, projecting 14-15% growth; gross profit margin expected at 62%, operating margin at 21%
  • 15-day G7 sensor launch and international market expansion were key growth drivers; company maintains 'GREAT' financial health score of 3.17
  • Jake Leach named as incoming CEO, emphasizing focus on expanding access to DexCom's technology and continued strong category growth
Last Updated: 30/07/2025, 23:30
Read Full Transcript

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
54.4x−3.8x−0.5x
PEG Ratio
−4.77−0.270.00
Price/Book
12.1x2.8x2.6x
Price / LTM Sales
7.2x3.1x3.3x
Upside (Analyst Target)
28.7%36.2%45.4%
Fair Value Upside
Unlock6.2%7.7%Unlock

Analyst Ratings

22 Buy
4 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 102.08
(+28.76% Upside)

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
0.48 / 0.45
Revenue / Forecast
1.16B / 1.12B
EPS Revisions
Last 90 days

DXCM Income Statement

People Also Watch

193.33
LULU
-3.59%
131.95
BIIB
+3.09%
56.82
ON
+0.82%
356.97
CDNS
-2.08%
74.45
MRVL
-7.37%

FAQ

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 31.09B.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 1.46.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 10250 employees.

What is the current trading status of DexCom (DXCM)?

As of 03 Aug 2025, DexCom (DXCM) is trading at a price of 79.28, with a previous close of 80.77. The stock has fluctuated within a day range of 78.93 to 80.86, while its 52-week range spans from 57.52 to 93.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.